Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004258 · ClinicalTrials.gov registry record · Phase 1
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
A Phase 1 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00004258 is a Phase 1 study that has completed, run by Indiana University. The registered enrollment target is 40 participants.
The verdict
NCT00004258, a Phase 1 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of EMD 121974 in treating patients who have locally advanced or metastatic cancer.
Interventions
- DRUG cilengitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1999-12 |
| Est. Completion | 2001-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004258
The ClinicalTrials.gov registry entry for NCT00004258 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cilengitide is the first listed.
NCT00004258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004258 about?
NCT00004258 is a clinical study titled "EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer". RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of EMD 121974 in treating patients who have locally advanced or metastatic cancer.
What is the current status of trial NCT00004258?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 1999-12. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00004258?
The interventions under investigation include: cilengitide (DRUG).
Who is sponsoring clinical trial NCT00004258?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.